about
Strengthening drug policy and practice through ethics engagement: an old challenge for a new harm reduction.Ethical questions must be considered for electronic health records.Transient changes in behaviour lead to heroin overdose: results from a case-crossover study of non-fatal overdose.Drug use and risk among regular injecting drug users in Australia: does age make a difference?Paying research participants: a study of current practices in Australia.Quantifying hepatitis C transmission risk using a new weighted scoring system for the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ): applications for community-based HCV surveillance, education and prevention.Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia.Comparing probability and non-probability sampling methods in Ecstasy research: implications for the internet as a research tool.Pattern and characteristics of ecstasy and related drug (ERD) presentations at two hospital emergency departments, Melbourne, Australia, 2008-2010.Randomized controlled trial of a brief behavioural intervention for reducing hepatitis C virus risk practices among injecting drug users.Contemporary cocaine use patterns and associated harms in Melbourne and Sydney, Australia.An important, but not the first, hepatitis C virus behavioural intervention study.Harm reduction ethics: Acknowledging the values and beliefs behind our actions.Australian resources for ethical participatory processes in public health research.Research participation and internal normativity: understanding why people participate.Using ambulance attendances to recruit people who have experienced non-fatal heroin overdose.Recent trends in benzodiazepine use by injecting drug users in Victoria and Tasmania.Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ).Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics.Engaging the values-based ethical dilemmas in harm minimization: a response to Weatherburn.Positive and negative aspects of participation in illicit drug research: implications for recruitment and ethical conduct.Ethical implications of peer-driven recruitment: guidelines from public health research.How to build a theory about empirical bioethics: acknowledging the limitations of empirical research.Challenges of reliability and validity in the identification and monitoring of emerging drug trends.Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia.Raising the profile of human research ethics in addictions research: a key role for addictions journals.The place of supervised injecting facilities within harm reduction: evidence, ethics and policy.Applied communitarian ethics for harm reduction: promoting a dialogue within the field.A survey of regular ecstasy users’ knowledge and practices around determining pill content and purity: Implications for policy and practiceUnresolved Ethical Challenges for the Australian Personally Controlled Electronic Health Record (PCEHR) System: Key Informant Interview FindingsToward a Lay Descriptive Account of Identity in Addiction NeuroethicsThe Unique Nature of Clinical Ethics in Allied Health Pediatrics: Implications for Ethics EducationA Descriptive Social Neuroethics is Needed to Reveal Lived IdentitiesA comprehensive evidence-based approach is needed for promoting participation in health research: A commentary on WilliamsApplied ethical reflections on the operation of a Geneva drug consumption room: Opportunities for enhanced harm reduction practiceScience, ethics and the regulation of alcohol and other drug researchWhen is a little knowledge dangerous?Circumstances of recent heroin overdose and links to knowledge of overdose risk factorsEthical Considerations for Drug Abuse Epidemiologic ResearchThe ethics of reimbursing injecting drug users for public health research interviews: what price are we prepared to pay?
P50
Q30363350-CB6CE7B9-B3ED-4865-BD7F-17FA467E8FBDQ34273929-D5856225-C7C5-4E8C-99EF-54E78B9660CEQ34413365-4862445D-A575-47A0-9AF8-58D4962C656AQ34789721-068E7A2B-44FB-4A62-8CF0-56D150B2DA8EQ35430679-C3B4C9F3-DA75-46B3-BBD5-FB4EE31FF2E2Q36663249-8417D09D-5BEA-400E-9984-BDDE88EE168AQ39739134-10D41835-47C6-40D3-A014-B9EDD64E4C4FQ39902552-B7BDDFA6-4BEA-4EB9-813C-0AE34BCD8D9BQ40091993-11D66784-020E-4F8C-8D96-420DCD8AA33AQ40488636-7E0DF534-5143-4B88-9E12-31C3D06A2F1FQ42629180-DF7965B0-4D5A-4497-93AF-842A9FC3C6C0Q43048067-B3221AA9-0D5B-4492-9580-ADB7748684AFQ43076783-C9759C30-EF39-4DF5-8093-D822B85D2E49Q43238785-748DAF4B-7581-4421-98A9-A610433D3574Q43486872-DF724D54-A192-474B-8DF0-6AAF80AE3652Q44026553-5AB0F0D4-5D53-42A2-9BF7-E1BE3A5F79BAQ44284791-4448D4D3-1A8B-4B07-B589-E2CA300A5780Q45243717-CD249B06-7092-4100-B90F-DF67782A3DBCQ45729494-C066E543-3CB3-423B-8414-7C7A75327149Q46813118-BB960487-B554-411A-9466-AFB1367E98B8Q48282707-42CD9325-D8D4-4408-80EA-C2D7DEFC997FQ48389307-7B01DBA9-4DA5-42EF-8E57-87267C3CC49FQ48863432-33815E48-304F-427E-B01B-6BC6B65DC9EAQ48937040-143203AB-DBB4-4778-AEFC-0127CB6DE309Q50155270-A882D97F-9BC8-49D1-976A-AB12DFF4E29CQ50788028-966B70DA-BAA3-47FB-9804-CAFB0155AA7FQ52280757-9E0A23AD-0B4F-4A1A-9EE8-4FA0E69A4155Q52288915-EAA48412-C743-4356-81A7-9AAA5E65D7AFQ53180494-3DDF52CF-F91F-42E5-8ACA-4ABBD6427A1AQ57047618-4AA37FCF-0BF9-4111-B046-998F2E1D8E72Q57660245-1A200539-2332-4419-B28F-4CC4AA6B0CA2Q57660256-6399D305-4CCF-404A-B25F-B4878FC460BFQ57660264-D17650AC-E9EF-4E5D-BAB8-CCEE97EF0A73Q57660273-9BF2FEBC-3BF5-4380-9843-9C4C2BB059C3Q57660278-D98AE161-946C-4B07-B321-A42E088959B2Q57660301-52B48F08-3B10-4E1C-A610-5BB2D142360BQ57660307-DDDAA66D-49BA-4B67-843E-D2CF9F5E6E0BQ57660311-FAF42989-728A-4345-B900-8F00CE4D3A44Q57660317-A09DF33B-3BE1-40AE-86BA-19073E404EB3Q57660332-4A4CC134-6E5E-4CB4-8094-599A53B06AFB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Craig L Fry
@nl
Craig L Fry
@sl
Craig L. Fry
@en
Craig L. Fry
@es
type
label
Craig L Fry
@nl
Craig L Fry
@sl
Craig L. Fry
@en
Craig L. Fry
@es
altLabel
Craig Fry
@en
Craig L Fry
@en
Craig L M Fry
@en
Fry C
@en
prefLabel
Craig L Fry
@nl
Craig L Fry
@sl
Craig L. Fry
@en
Craig L. Fry
@es
P106
P1153
7102479784
P21
P2798
P31
P496
0000-0001-7867-4388